• Monday, June 26, 2023 @ 12:00 am

The Catalyst licensing deal for vamorolone rights in North America, valued at up to USD 231 mn plus royalties, significantly improves the risk/reward profile for Santhera avoiding substantial dilution to raise cash for a US sales force, extends the cash runway into Q1 2025 and an experienced partner for North America.

Key catalysts include:

  1. Vamorolone US approval in DMD - PDUFA (26 October 2023)
  2. Vamorolone EU approval in DMD (Q4 2023)
  3. Vamorolone UK approval in DMD (Q4 2023)

Read the full Santhera Valuation Report